Tumor mutational burden (TMB) has emerged as a predictive biomarker of response to immune checkpoint inhibitors. Standardization of TMB measurement is essential for implementing diagnostic tools to gu

NIAID Data Ecosystem110

DataSheet_1_ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer.docx

非小细胞肺癌免疫治疗生物标志物

SWI/SNF基因突变预测ICIs疗效

Worldwide, non-small cell lung cancer (NSCLC) has the highest morbidity and mortality of all malignancies. The lack of responsiveness to checkpoint inhibitors is a central problem in the modern era of

NIAID Data Ecosystem60

ena-DATASET-MUG-10-03-2014-09:03:11:084-191 - samples

靶向深度测序

突变等位基因频率

We used targeted deep sequencing to accurately establish the allele frequencies of the mutations identified by exome sequencingEGA dataset EGAD00001000763

NIAID Data Ecosystem40